From current status to optimization of HCV treatment: Recommendations from an expert panel

Digestive and Liver Disease

Volumn 48, Issue 9, 2016, Pages 995-1005

  Craxì, Antonio ^r   Perno, Carlo Federico ^s   Viganò, Mauro ^a   Ceccherini Silberstein, Francesca ^s   Petta, Salvatore ^r   Aghemo, Alessio ^a   Alberti, Alfredo ^b   Andreone, Pietro ^c   Andreoni, Massimo ^c   Bonora, Stefano ^d   Brunetto, Maurizia Rossana ^e   Bruno, Savino ^f   Caporaso, Nicola ^g   Chirianni, Antonio ^h   Ciancio, Alessia ^d   Degasperi, Elisabetta ^a   Di Perri, Giovanni ^d   Fagiuoli, Stefano ⁱ   Ferrari, Carlo ^j   Gaeta, Giovanni Battista ^k   Pellicelli, Adriano ^l   Puoti, Massimo ^m   Raimondo, Giovanni ⁿ   Taliani, Gloria ^o   Villa, Erica ^p   Zignego, Anna Linda ^q   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f HUMANITAS UNIVERSITY   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Azienda Ospedaliera di Rilievo Nazionale D Cotugno   (Italy)

ⁱ PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^j UNIVERSITY HOSPITAL OF PARMA   (Italy)

^k SECOND UNIVERSITY OF NAPLES   (Italy)

^l SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^m OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁿ UNIVERSITY OF MESSINA   (Italy)

^o SAPIENZA UNIVERSITY OF ROME   (Italy)

^p UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^q UNIVERSITY OF FLORENCE   (Italy)

^r UNIVERSITY OF PALERMO   (Italy)

^s UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Antiviral therapy; Cirrhosis; Direct acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; ALPHA INTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER GRAFT; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MEDICAL SOCIETY; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COINFECTION; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; SOCIETIES, MEDICAL; VIRAL LOAD;

EID: 84986601943     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.06.004     Document Type: Article

References (97)

1. [1] Webster, D.P., Klenerman, P., Dusheiko, G.M., et al. Lancet 385 (2015), 1124–1135.
2. [2] Negro, F., Forton, D., Craxì, A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
3. [3] Viganò, M., Colombo, M., Extrahepatic manifestations of hepatitis C virus. Gastroenterology Clinics of North America 44 (2015), 775–791.
4. [4] World Health Organization, Global burden of disease (GBD) for hepatitis C. Journal of Clinical Pharmacology 44 (2004), 20–29.
5. [5] Alter, M.J., Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 13 (2007), 2436–2441.
6. [6] Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
7. [7] AASLD/IDSA Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
8. [8] EASL, Recommendations on treatment of hepatitis C 2015. Journal of Hepatology 63 (2015), 199–236.
9. [9] AISF. Documento di indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammessi alla rimborsabilità in Italia. http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2015.aspx [accessed February 2016].
10. [10] Simmons, B., Saleem, J., Heath, K., et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clinical Infectious Diseases 61 (2015), 730–740.
11. [11] Hsu, Y.-C., Lin, J.-T., Ho, H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
12. [12] Arase, Y., Suzuki, F., Suzuki, Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49 (2009), 739–744.
13. [13] Hsu, Y.C., Ho, H.J., Huang, Y.T., et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64 (2015), 495–503.
14. [14] van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
15. [15] Backus, L.I., Boothroyd, D.B., Phillips, B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology 9 (2011), 509–516.
16. [16] Bruno, S., Crosignani, A., Facciotto, C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
17. [17] Bruno, S., Stroffolini, T., Colombo, M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
18. [18] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antiviral Therapy 16 (2011), 677–684.
19. [19] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
20. [20] Morisco, F., Granata, R., Stroffolini, T., et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World Journal of Gastroenterology 19 (2013), 2793–2798.
21. [21] Bruno, S., Boccaccio, V., Russo, M.L., et al. Is the benefit of treating patients with cirrhosis proven?. Liver International 36 (2016), S21–S27.
22. [22] Leroy, V., Angus, P.W., Bronowicki, J.P., et al. All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. Hepatology, 2016, 10.1002/hep.28473 [Epub ahead of print].
23. [23] Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New England Journal of Medicine 370 (2014), 1973–1982.
24. [24] Reddy, K.R., Bourlière, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
25. [25] Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology, 2015, 10.1002/hep.28422 [Epub ahead of print].
26. [26] Hèzode, C., De Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program Hepatology, 62(Suppl. 1), 2015, 315A.
27. [27] Chevaliez, S., Bouvier-Alias, M., Brillet, R., et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE, 4, 2009, e8209.
28. [28] Ceccherini Silberstein, F., Di Maio, V.C., Aragri, M., et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology, 2015, 10.1002/hep.27895 [Epub ahead of print].
29. [29] Bochud, P.Y., Cai, T., Overbeck, K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 51 (2009), 655–666.
30. [30] Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New England Journal of Medicine 370 (2014), 1993–2001.
31. [31] Foster, G., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
32. [32] Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
33. [33] Hèzode, C., et al., De Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology, 62(Suppl. 1), 2015, 315A.
34. [34] Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 64 (2016), 486–504.
35. [35] Nelson, D.R., Abstract from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Berlin 26–28th June. 2015.
36. [36] Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New England Journal of Medicine 370 (2014), 1983–1992.
37. [37] Andreone, P., Colombo, M.G., Enejosa, J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365.
38. [38] FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm.
39. [39] Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1889–1898.
40. [40] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1483–1493.
41. [41] Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370 (2014), 1879–1888.
42. [42] Terrault, N., Zeuzem, S., Di Bisceglie, A.M., et al. Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational Study. Hepatology, 62(Suppl. 1), 2015, 256A.
43. [43] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 370 (2014), 211–221.
44. [44] Poordad, F., Shiff, E.R., Vierling, J.M., et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Journal of Hepatology 62 (2015), S261–S262.
45. [45] Jacobson, I.M., Asante-Appiah, E., Wong, P., et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection. Hepatology, 62, 2015, 1393A.
46. [46] Feld, J.J., Agarwal, K., Hezode, C., et al. A phase 3 double-blind placebo-controlled evaluation of Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in naïve and experienced Genotype 1, 2, 4, 5, 6 HCV infected patients with and without cirrhosis: results of the ASTRAL-1 study. Hepatology, 62, 2015, 1379A.
47. [47] Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. New England Journal of Medicine 373 (2015), 2618–2628.
48. [48] Kirk, G.D., Mehta, S.H., Astemborski, J., et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Annals of Internal Medicine 158 (2013), 658–666.
49. [49] Lo Re, V., Kallan, M.J., Tate, J.P., et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of Internal Medicine 160 (2014), 369–377.
50. [50] Pircher, J., Czermak, T., Merkle, M., et al. Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2. PLoS ONE, 9, 2014, e113351.
51. [51] Hernando, V., Perez-Cachafeiro, S., Lewden, C., et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. Journal of Hepatology 57 (2012), 743–751.
52. [52] Naggie, S., Cooper, C., Saag, M., et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 705–713.
53. [53] Sulkowski, M.S., Eron, J.J., Wyles, D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313 (2015), 1223–1231.
54. [54] Wyles, D.L., Ruane, P.J., Sulkowski, M.S., et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 714–725.
55. [55] Pulido, F., Hill, A., van Delft, Y., et al. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Reviews 14 (2012), 124–131.
56. [56] Gordon, S.C., Sherman, K.E., Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology 136 (2009), 393–396.
57. [57] Liu, C.J., Chuang, W.L., Lee, C.M., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136 (2009), 496–504.
58. [58] Takayama, H., Sato, T., Ikeda, F., et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatology Research, 2015, 10.1111/hepr.12578 [Epub ahead of print].
59. [59] Collins, J.M., Raphael, K.L., Terry, C., et al. Virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clinical Infectious Diseases 61 (2015), 1304–1306.
60. [60] Cacoub, P., Gragnani, L., Comarmond, C., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Digestive and Liver Disease 46:Suppl. 5 (2014), S165–S173.
61. [61] Zignego, A.L., Ferri, C., Pileri, S.A., et al. For the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and Liver Disease 39 (2007), 2–17.
62. [62] Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the Rheumatic Diseases, 2015 [Epub ahead of print].
63. [63] Michot, J.M., Canioni, D., Driss, H., et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. American Journal of Hematology 90 (2015), 197–203.
64. [64] Gragnani, L., Piluso, A., Urraro, T., et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Current Drug Targets, 2016 [Epub ahead of print].
65. [65] Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
66. [66] Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial. Lancet Infectious Diseases, 2016, 10.1016/S1473-3099(16)00052-9 [Epub ahead of print].
67. [67] Foster, G., Irving, W., Cheung, M.C.M., et al. Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 10.1016/j.jhep.2016.01.029 [in press].
68. [68] Reddy, R., Lim, J.K., Kuo, A., et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. Journal of Hepatology, 62, 2015, S193.
69. [69] Saxena, V., Nyberg, L., Pauly, M.P., et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology 62 (2015), 715–725.
70. [70] Jacobson, I.M., Poordad, F., Firpi-Morell, R., et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A). Journal of Hepatology, 62, 2015, S193.
71. [71] Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.
72. [72] Burgess, S., Partovi, N., Yoshida, E.M., et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Annals of Pharmacotherapy 49 (2015), 674–687.
73. [73] Fontana, R.J., Brown, R., Herzer, J., et al. Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection. Journal of Hepatology, 62, 2015, S629.
74. [74] Forns, X., Charlton, M., Denning, J., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
75. [75] Pungpapong, S., Aqel, B., Leise, M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
76. [76] Kwo, P.Y., Mantry, P.S., Coakley, E.T., et al. An interferon-free antiviral regimen for HCV after liver transplantation. New England Journal of Medicine 371 (2014), 2375–2382.
77. [77] Charlton, M., Gane, E., Manns, M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
78. [78] Pellicelli, A.M., Montalbano, M., Lionetti, R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease 46 (2014), 923–927.
79. [79] Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV. Journal of Hepatology, 62, 2015, S620.
80. [80] McPhee, F., Hernandez, D., Zhou, N., et al. Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis. Hepatology, 62(Suppl. 1), 2015, 560A.
81. [81] Lontok, E., Harrington, P., Howe, A., et al. Hepatitis C virus drug resistance – associated substitutions: state of the art summary. Hepatology 62 (2015), 1623–1632.
82. [82] Di Maio, V.C., Cento, V., Di Paolo, D., et al. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for retreatment. DLD, 48(Suppl. 2), 2016, 10.106/j.dld.2015.12.022 [Abstract AISF 2016].
83. [83] Krishnan, P., Tripathi, R., Schnell, G., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir. Antimicrobial Agents and Chemotherapy 59 (2015), 5445–5454.
84. [84] Gane, E.J., Abergel, A., Metivier, S., et al. The emergence of NS5B Resistant associated variant S282T after Sofosbuvir-based treatment. Hepatology, 62, 2015, S322A.
85. [85] Osinusi, A., Marti, M., Townsend, K., et al. Retreatment of relapsers to Sofosbuvir/Ribavirin with Sofosbuvir/Ledipasvir: complete and rapid virologic suppression by week 4. Journal of Hepatology, 60, 2014, S56.
86. [86] Wyles, D., Pockros, P., Morelli, G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 61 (2015), 1793–1797.
87. [87] Lenz, O., Verbinnen, T., Fevery, B., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of Hepatology 62 (2015), 1008–1014.
88. [88] Krishnan, P., Schnell, G., Tripathi, R., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy 60 (2015), 1106–1113.
89. [89] Black, S., Pak, I., Ingravallo, P., et al. Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-Worthy study. Journal of Hepatology 62 (2015), S677–S678.
90. [90] Di Maio, V.C., Armenia, D., Bellocchi, M.C., et al. Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing. Journal of Hepatology, 62, 2015, S688.
91. [91] Dvory-Sobol, H., Wyles, D., Ouyang, W., et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Journal of Hepatology, 62, 2015, S221.
92. [92] Wang, C., Sun, J.H., O'Boyle, D.R., et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrobial Agents and Chemotherapy 57 (2013), 2054–2065.
93. [93] Nakamoto, S., Kanda, T., Wu, S., et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World Journal of Gastroenterology 20 (2014), 2902–2912.
94. [94] Lawitz, E., Flamm, S., Yang, J.C., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Journal of Hepatology, 62, 2015, S192.
95. [95] Hezode, C., Chevaliez, S., Scoazec, G., et al. Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen. Hepatology, 62(Suppl. 2), 2015, 763A.
96. [96] Lawitz, E., Poordad, F., Gutierrez, J.A., et al. Results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease. Hepatology, 62(Suppl. 1), 2015, S227A.
97. [97] Poordad, F., Bennett, M., Sepe, T.E., et al. Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir. Hepatology, 62(Suppl. 1), 2015, 1392A.